Related Experiment Videos
Gemcitabine-associated hemolytic-uremic syndrome
Roland B Walter1, Markus Joerger, Bernhard C Pestalozzi
1Medical Clinic B and Division of Oncology, Department of Internal Medicine, University Hospital, Zürich, Switzerland. rwalter@fhcrc.org
Summary
Gemcitabine can cause hemolytic-uremic syndrome (HUS), a rare but serious condition. Early recognition and discontinuation of gemcitabine are crucial for patient recovery from this potentially fatal side effect.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- Gemcitabine is a widely used chemotherapy agent with known mild renal toxicity.
- Rare cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been documented.
Observation:
- A case of a 45-year-old woman with ovarian cancer who developed HUS during prolonged gemcitabine treatment is presented.
- Literature review identified 26 cases of gemcitabine-associated HUS, with a median patient age of 52.
- Onset of HUS occurred at a median of 7.4 months or 21.9 doses of gemcitabine, with a median cumulative dose of 20,000 mg/m².
Findings:
- Diagnosis of HUS was confirmed histologically or clinically.
- Treatment strategies included drug discontinuation, steroids, plasma exchange, and dialysis.
- Mortality was high, with 11 of 23 patients dying within weeks; re-exposure to gemcitabine was problematic in most cases.
Implications:
- Gemcitabine-associated HUS is a rare but potentially fatal complication.
- Prompt recognition and cessation of gemcitabine therapy are critical.
- Healthcare providers should be aware of this severe adverse event associated with gemcitabine chemotherapy.